Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Behr, R. Million-Rousseau, A. Morganti, L. Perchenet, G. Raghu (Bochum, Germany; Allschwil, Switzerland; Seattle, United States Of America). MUSIC: Efficacy and safety of macitentan in idiopathic pulmonary fibrosis (IPF). Eur Respir J 2012; 40: Suppl. 56, 1778

Member's Comments

Issac T.J.Barney - 02.09.2012 04:52
Why is there a discrepancy in the number of patients in the macitentan group and the placebo group. Was block randomistaion used?

Related content which might interest you: Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2006; 28: Suppl. 50, 767s Year: 2006 The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Late Breaking Abstract - Pharmacokinetics (PK) of nintedanib with add-on pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): results from INJOURNEY Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 LATE-BREAKING ABSTRACT: Safety and tolerability of N-acetylcysteine (NAC) with pirfenidone in idiopathic pulmonary fibrosis (IPF): PANORAMA Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012 Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial Source: International Congress 2018 – Clinical news in idiopathic interstitial pneumonias Year: 2018 Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Pirfenidone treatment for idiopathic pulmonary fibrosis (IPF): a comprehensive analysis of safety Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009 Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1382-1392 Year: 2015 Bosentan in idiopathic pulmonary fibrosis (IPF) patients: the BUILD 1 study Source: Eur Respir J 2006; 28: Suppl. 50, 383s Year: 2006 Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Long-term tolerability of real-life use of antifibrotic agents (AFA) in Idiopathic Pulmonary Fibrosis (IPF) Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 A comparison of pirfenidone versus nintedanib for the management of idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016